The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSUPP.L Regulatory News (SUPP)

  • There is currently no data for SUPP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Investment in Attest

18 Nov 2021 07:00

RNS Number : 7461S
Schroder UK Public Private Tst plc
18 November 2021
 

Schroder UK Public Private Trust plc

Investment in Attest

Schroder UK Public Private Trust plc (the "Company") is pleased to announce it has made a $7.0 million investment in leading market research technology platform, Attest Technologies Limited ("Attest"), as part of its $64 million Series B funding round. The investment in Attest is the third new private equity investment since the appointment of Schroder Investment Management Ltd as the Company's portfolio manager and further progresses the continued rebalancing of the portfolio with Attest being the first business services sector investment to enter the portfolio.

Attest's Series B funding was led by an undisclosed growth investor with participation from specialist tech investment firm Kismet and existing investor, leading global venture capital firm NEA.

Attest has built an intuitive software as a service platform which aims to make checking ideas and actions with target consumers as second-nature as checking the time, so every business decision can be grounded in data. Using Attest's technology, surveys can be created and distributed to target consumers in as little as 90 seconds and results are significantly higher-quality, more reliable, representative, and delivered faster than ever previously possible. This self-serve technology is supported by Attest's in-house team of research experts, leading to trustworthy data that brands can rely on.

Attest has achieved record revenue growth during the pandemic, driving the accelerated importance of customer and market understanding to organisations who are seeking competitive advantage and business growth. Attest has continued to support and grow its ever-expanding client base, including Microsoft, Santander, Walgreens/Boots, Wise, Klarna, Organic Valley and Fabletics. Attest's consumer reach has also increased, with brands now able to access more than 110 million people in 49 countries. Via Attest, this power is now open to any user, in any business to consumer company, on-demand any time.

This latest round will help further accelerate Attest's expansion in both Europe and North America, as well as the company's mission to make high quality research simple, fast and powerful for everyone on a continuous basis.

This investment is in line with the Company's focus on backing innovative UK businesses with disruptive innovation, significant global growth potential, high quality management teams and supported by highly reputable co-investors. The Company is committed to improving its sustainability profile and intends to disclose where appropriate the United Nations' Sustainable Development Goals ("SDGs") associated with new investments. The investment in Attest is in line with SDG 8 "Decent Work and Economic Growth" and Target 8.2 "Achieve higher levels of economic productivity through diversification, technological upgrading and innovation, including through a focus on high-value added and labour-intensive sectors".

 

Tim Creed and Roger Doig, Portfolio Managers of the Company, jointly commented: "We are delighted to announce the third new private equity investment since our appointment as portfolio manager. We believe Attest represents a high-quality addition to the portfolio with significant growth potential. In the current business climate, the importance of operating in a customer-centric manner and continually monitoring consumer behaviour has never been greater and Attest is revolutionising access to high quality insights for brands around the world. The company's ambition to make market research available to everyone and democratise data represents a sizeable market opportunity which is multiples of the existing traditional market research sector. We look forward to supporting the company on its journey over the coming years".

 

Enquiries:

Schroder Investment Management Limited

Estelle Bibby (Press)

0207 658 3431

Gareth Faith (Company Secretary)

0207 658 5264

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBRBPTMTJBBAB
Date   Source Headline
20th Apr 20233:55 pmRNSChange of Name
20th Apr 202310:52 amRNSNet Asset Value(s)
19th Apr 202312:06 pmRNSNet Asset Value(s)
19th Apr 202312:02 pmRNSNet Asset Value(s)
19th Apr 202311:24 amRNSNet Asset Value(s)
19th Apr 20237:00 amRNSAnnual Financial Report on NSM
18th Apr 20236:00 pmRNSNet Asset Value(s) - Replacement
18th Apr 202312:08 pmRNSNet Asset Value(s)
17th Apr 202311:09 amRNSNet Asset Value(s)
17th Apr 20237:00 amRNSFinal Results
14th Apr 202310:47 amRNSNet Asset Value(s)
15th Mar 202310:51 amRNSNet Asset Value(s)
15th Mar 20237:00 amRNSUpdate on Silicon Valley Bank
14th Mar 202311:11 amRNSNet Asset Value(s)
13th Mar 202311:19 amRNSNet Asset Value(s)
10th Mar 202311:16 amRNSNet Asset Value(s)
9th Mar 202310:46 amRNSNet Asset Value(s)
8th Mar 202310:54 amRNSNet Asset Value(s)
7th Mar 20235:44 pmRNSHolding(s) in Company
7th Mar 20235:30 pmRNSHolding(s) in Company
7th Mar 202310:16 amRNSNet Asset Value(s)
6th Mar 202310:26 amRNSNet Asset Value(s)
3rd Mar 202310:27 amRNSNet Asset Value(s)
2nd Mar 202310:35 amRNSNet Asset Value(s)
1st Mar 202310:41 amRNSNet Asset Value(s)
28th Feb 20234:50 pmRNSTotal Voting Rights
28th Feb 202310:26 amRNSNet Asset Value(s)
27th Feb 202311:27 amRNSNet Asset Value(s)
24th Feb 202311:44 amRNSBlock listing Interim Review
24th Feb 202310:52 amRNSNet Asset Value(s)
23rd Feb 202310:57 amRNSNet Asset Value(s)
22nd Feb 202310:50 amRNSNet Asset Value(s)
21st Feb 202311:19 amRNSNet Asset Value(s)
20th Feb 202310:57 amRNSNet Asset Value(s)
17th Feb 202310:53 amRNSNet Asset Value(s)
16th Feb 202310:53 amRNSNet Asset Value(s)
15th Feb 202310:53 amRNSNet Asset Value(s)
14th Feb 202311:18 amRNSNet Asset Value(s)
13th Feb 202311:54 amRNSNet Asset Value(s)
10th Feb 20234:49 pmRNSTransaction in Own Shares
10th Feb 202311:19 amRNSNet Asset Value(s)
9th Feb 202311:25 amRNSNet Asset Value(s)
8th Feb 20235:08 pmRNSTransaction in Own Shares
8th Feb 202310:46 amRNSNet Asset Value(s)
7th Feb 202311:12 amRNSNet Asset Value(s)
6th Feb 202311:13 amRNSNet Asset Value(s)
3rd Feb 20235:02 pmRNSTransaction in Own Shares
3rd Feb 202311:05 amRNSNet Asset Value(s)
2nd Feb 20234:49 pmRNSHolding(s) in Company
2nd Feb 20232:50 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.